Type II diabetes (T2D) is a major global health problem (Banerjee, Nema, Dhas, & Mishra, 2017), and its prevalence is rapidly increasing throughout the world (Hu et al., 2015). According to an International Diabetes Federation (IDF) report, 382 million adults in the world had diabetes in 2013 (Han, Kim, Kim, Lee, & Cho, 2017) and this figure is expected to reach 592 million by 2035 (Guariguata et al., 2014). The mentioned statistic also suggests that most of the diabetes patients will have T2D (Han et al., 2017). Currently, more than 4 million people have diabetes in Iran and this figure triples every 15 years (Esteghamati et al., 2014; Zendehtalab, Vaghei, & Emamimoghadam, 2013). According to the experts' unofficial predictions, the diabetes population of Iran will reach nine million by 2020 (Rohani et al., 2016). However, the prevalence of T2D is estimated to be 8.6% in Iran (Nosratabadi, Halvaiepour, Yousefi, & Karimi, 2016). The increasing prevalence of diabetes leads to extensive treatment costs. In this regard, in the United States, the total cost of DM amounts to $2108/patient per year (Leon & Maddox, 2015), because diabetes is associated with an increased risk of cardiac, renal and neurological diseases, visual impairment and early mortality (Baraz,